Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference25 articles.
1. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007
2. Efficacy of everolimus in advanced renal-cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
3. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal-cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007
4. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal-cell carcinoma: CALGB 90206;Rini;J Clin Oncol,2008
5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
Cited by 364 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Own experience of using combination therapy in the first line of treatment of metastatic renal cell carcinoma;Meditsinskiy sovet = Medical Council;2024-07-24
2. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data;Clinical Genitourinary Cancer;2024-06
3. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy;Nature Communications;2024-04-27
4. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma;Cancer Immunology, Immunotherapy;2024-04-20
5. Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications;European Journal of Clinical Pharmacology;2024-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3